Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) Products under Development by Stage of Development | 8 | 1 |
| Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) Products under Development by Therapy Area | 9 | 1 |
| Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) Products under Development by Indication | 10 | 2 |
| Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) Products under Development by Companies | 14 | 3 |
| Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) Products under Development by Universities/Institutes | 17 | 2 |
| Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) Therapeutics Assessment | 19 | 6 |
| Assessment by Monotherapy/Combination Products | 19 | 1 |
| Assessment by Mechanism of Action | 20 | 1 |
| Assessment by Route of Administration | 21 | 2 |
| Assessment by Molecule Type | 23 | 2 |
| Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) Companies Involved in Therapeutics Development | 25 | 6 |
| CanBas Co., Ltd. | 25 | 1 |
| Cascadian Therapeutics Inc | 26 | 1 |
| Eli Lilly and Company | 27 | 1 |
| Genentech, Inc. | 28 | 1 |
| Sareum Holdings Plc | 29 | 1 |
| Vernalis Plc | 30 | 1 |
| Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) Drug Profiles | 31 | 16 |
| CBP-501 Drug Profile | 31 | 2 |
| CCT-244747 Drug Profile | 33 | 2 |
| CCT-245737 Drug Profile | 35 | 2 |
| FS-105 Drug Profile | 37 | 1 |
| ONT-2409 Drug Profile | 38 | 1 |
| prexasertib Drug Profile | 39 | 2 |
| RG-7741 Drug Profile | 41 | 1 |
| SAR-020106 Drug Profile | 42 | 2 |
| Small Molecule to Inhibit Chk1 for Cancer Drug Profile | 44 | 1 |
| Small Molecules to Inhibit Chk1 for Oncology Drug Profile | 45 | 1 |
| V-158411 Drug Profile | 46 | 1 |
| Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) Dormant Projects | 47 | 1 |
| Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) Discontinued Products | 48 | 1 |
| Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) Featured News &Press Releases | 49 | 8 |
| May 23, 2016: Clinical Trials of CHK1 Inhibitor CCT245737 to Open at the Royal Marsden Hospital | 49 | 1 |
| Apr 19, 2016: Oncothyreon Highlights Novel Checkpoint Kinase 1 Inhibitors at American Association for Cancer Research (AACR) Annual Meeting 2016 | 49 | 1 |
| Apr 05, 2016: CHK1 inhibitor CCT245737 Approved for Clinical Trials in Cancer Patients | 50 | 1 |
| Feb 01, 2016: CHK1 Clinical Trial Application Submissions | 50 | 1 |
| Dec 15, 2015: CHK1 Clinical Trial Applications | 50 | 1 |
| May 12, 2015: Sareum to Present at BioTrinity 2015 | 51 | 1 |
| Apr 20, 2015: Lilly Releases Early-Stage Pipeline Data On LY2606368 at AACR Annual Meeting 2015 | 51 | 1 |
| Apr 17, 2013: CanBas Announces Topline Results From Phase II Trial Of CBP501 In Patients With Non-Small Cell Lung Cancer | 52 | 1 |
| Jun 04, 2012: CanBas's CBP501 Meets Primary Endpoint In Phase II Study Of Malignant Pleural Mesothelioma | 53 | 1 |
| Jan 05, 2012: CanBas's CBP501 Receives Orphan Drug Designation From FDA For Malignant Mesothelioma | 53 | 1 |
| Nov 01, 2011: Canbas Enrolls Last Patient In Phase II Trial Of CBP501 As First-Line Treatment Of Malignant Pleural Mesothelioma | 54 | 1 |
| Oct 27, 2011: Canbas Announces Last Patient Enrolled In Phase II Trial Of CBP501 As First-Line Treatment Of Non-Small Cell Lung Cancer | 54 | 1 |
| Jan 20, 2010: New Molecules SAR-020106 Increase The Effectiveness Of Certain Cancer Therapies | 55 | 1 |
| Oct 06, 2009: Sareum And CRT Announce Results Of SAR-020106 At National Cancer Research Institute Cancer Conference | 55 | 1 |
| Jul 21, 2009: Vernalis Plc Announces New Oncology Development Candidate V158411 | 56 | 1 |
| Appendix | 57 | 2 |
| Methodology | 57 | 1 |
| Coverage | 57 | 1 |
| Secondary Research | 57 | 1 |
| Primary Research | 57 | 1 |
| Expert Panel Validation | 57 | 1 |
| Contact Us | 57 | 1 |
| Disclaimer | 58 | 1 |